BrianDWeissMD

Pediatric Hematology & Oncology • Indianapolis, IN

Pediatric Solid Tumor Oncology

Nora Letzter Professor of Pediatrics Chief, Division of Pediatric Hematology/Oncology/Stem Cell Transplant Indiana University School of Medicine Riley Hospital for Children

Join to view full profile

Dr. Weiss is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Weiss' full profile

Already have an account?

Office
Riley Hospital for Children
705 Riley Hospital Dr
Indianapolis, IN 46202
Phone+1 317-944-8784

Fax+1 513-636-3549
Is this information wrong?

Education & Training

University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 1997 - 2000
University of California (San Francisco)Chief Residency, Pediatrics, 1996 - 1997
University of California (San Francisco)Residency, Pediatrics, 1993 - 1996
Northwestern University The Feinberg School of MedicineClass of 1993

Certifications & Licensure

IN State Medical License 2021 - 2025
OH State Medical License 2003 - 2025
KY State Medical License 2021 - 2024
CA State Medical License 1995 - 2005
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Start of enrollment: 2008 Apr 01
Completed
Phase 2
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Start of enrollment: 2010 Oct 04
Active, not recruiting
Phase 1
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04
Active, not recruiting
Phase 1
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Start of enrollment: 2013 Aug 28
Completed
Phase 1
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 1
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Start of enrollment: 2014 Jun 01
Completed
Phase 2
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 2
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
Active, not recruiting
Phase 2
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Start of enrollment: 2020 Jun 11
Active, not recruiting
Phase 1
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs Start of enrollment: 2022 Aug 31
Active, not recruiting
Phase 2
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma Start of enrollment: 2021 Nov 18
Active, not recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

9 citations
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macro...
Benjamin J Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Brian D Weiss, Michelle Choe, Jennif...> ;Journal of Clinical Oncology. 2023 Jan 20
24 citations
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
Peter M K de Blank, Andrea M Gross, Srivandana Akshintala, Jaishri O Blakeley, Gideon Bollag, Ashley Cannon, Eva Dombi, Jason Fangusaro, Bruce D Gelb, Darren Hargrave,...> ;Neuro-Oncology. 2022 Nov 2
4 citations
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
Andrea M Gross, Brittany Glassberg, Pamela L Wolters, Eva Dombi, Andrea Baldwin, Michael J Fisher, AeRang Kim, Miriam Bornhorst, Brian D Weiss, Jaishri O Blakeley, Pat...> ;Neuro-Oncology. 2022 Nov 2
35 citations
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster, Suzanne Shusterman, Jane...> ;Neuro-Oncology. 2022 Oct 3
24 citations
Management of neurofibromatosis type 1-associated plexiform neurofibromas.
Michael J Fisher, Jaishri O Blakeley, Brian D Weiss, Eva Dombi, Shivani Ahlawat, Srivandana Akshintala, Allan J Belzberg, Miriam Bornhorst, Miriam A Bredella, Wenli Ca...> ;Neuro-Oncology. 2022 Nov 2
25 citations
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report ...
Steven G. DuBois, M. Meaghan Granger, Susan Groshen, Denice D. Tsao-Wei, Lingyun Ji, Anasheh Shamirian, Scarlett Czarnecki, Fariba Goodarzian, Rachel Berkovich, Hiroyu...> ;Journal of Clinical Oncology. 2021 Jul 16
8 citations
A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.
Brian Weiss, Gregory A. Yanik, Arlene Naranjo, Fan F Zhang, Wendy Fitzgerald, Barry L. Shulkin, Marguerite T. Parisi, Heidi V. Russell, Stephan A. Grupp, Luke Pater, P...> ;Pediatric Blood & Cancer. 2021 May 24
11 citations
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Tr...
M. Meaghan Granger, Arlene Naranjo, Rochelle Bagatell, Steven G. DuBois, Jeannine S. McCune, Sheena C. Tenney, Brian Weiss, Yael P. Mosse, Shahab Asgharzadeh, S. Grupp...> ;Transplantation and Cellular Therapy. 2021 Jun 1
2 citations
Metastatic neuroblastoma masquerading as infantile hemangioma in a 4‐month‐old child
Kristine Karkoska, Kiersten W. Ricci, Katherine VandenHeuvel, Andrew T. Trout, Ethan A. Smith, Meera Kotagal, Brian Weiss> ;Pediatric Blood & Cancer. 2021 Feb 28
2016 Children's Tumor Foundation Conference on Neurofibromatosis Type 1, Neurofibromatosis Type 2, and Schwannomatosis
Lu Q Le, Allan J Belzberg, Brigitte C Widemann, Brian Weiss, AeRang Kim, Matthias A Karajannis, Michael J Fisher, Nicole J Ullrich> ;American Journal of Medical Genetics Part A.
High-Dose Carboplatin/Etoposide/Melphalan Increases Risk of Thrombotic Microangiopathy and Organ Injury After Autologous Stem Cell Transplantation in Patients with Neu...
Christopher E Dandoy, Stella M Davies, Brian Weiss, Kasiani Myers, Gregory Wallace, Sonata Jodele> ;Nature.
13 citations
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine
Kelly E. Huibregtse, Kieuhoa T. Vo, Steven G. DuBois, Stephanie Fetzko, John Neuhaus, Vandana Batra, John M. Maris, Brian Weiss, Araz Marachelian, Greg Yanik, Katherin...> ;European Journal of Cancer. 2016 Oct 1
9 citations
Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1
Chie Emoto, Tsuyoshi Fukuda, Tomoyuki Mizuno, Shareen Cox, Björn Schniedewind, Uwe Christians, Brigitte C. Widemann, Michael Fisher, Brian Weiss, John P. Perentesis, A...> ;Therapeutic Drug Monitoring. 2015 Jun 1
15 citations
Update from the 2013 International Neurofibromatosis Conference.
Scott R. Plotkin, Anne C. Albers, Dusica Babovic-Vuksanovic, Jaishri O. Blakeley, Xandra O. Breakefield, Courtney M. Dunn, D. Gareth Evans, Michael Fisher, Jan M. Frie...> ;American Journal of Medical Genetics. Part A. 2014 Dec 1
43 citations
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors
Lars M. Wagner, Brian Turpin, Rajaram Nagarajan, Brian Weiss, Timothy P. Cripe, James I. Geller> ;Pediatric Blood & Cancer. 2013 Sep 1
4 citations
Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1.
Jeffrey R Scott, Joshua D Courter, Shannon N Saldaña, Brigitte C Widemann, Michael Fisher, Brian Weiss, John Perentesis, Alexander A Vinks> ;Therapeutic Drug Monitoring. 2013 Jun 1
Molecular therapies for tuberous sclerosis and neurofibromatosis.
Franz, D. N., Weiss, B. D.> ;Curr Neurol Neurosci Rep. 2012 Jun
5 citations
Use of sentinel node biopsy for staging parameningeal rhabdomyosarcoma.
Brian Weiss, Roshni Dasgupta, Michael J. Gelfand, Tal Laor, Hong Yin, John C. Breneman, Ruth Lavigne, Ravindhra G. Elluru, Lars M. Wagner> ;Pediatric Blood & Cancer. 2011 Sep 1
Join now to see all